How much progress was made on the PBGENE‑HBV program, and what are the next clinical milestones?

What the release tells us about PBGENE‑HBV

• The company states that its team is “very disciplined about executing our plans” and that it is “making strong progress advancing our clinical‑stage PBGENE‑HBV program.”
  
• No quantitative metrics (e.g., number of patients enrolled, trial sites opened, or specific regulatory filings) are given in the excerpt you provided. The language is intentionally broad, indicating that the program is moving forward on schedule but without revealing concrete milestones at this point.

Implied next clinical milestones

Although the press release does not list the exact upcoming steps, a typical development pathway for a clinical‑stage in‑vivo gene‑editing program such as PBGENE‑HBV would include the following milestones after “strong progress” has been reported:

Putting it together

• Progress to date: The company reports that PBGENE‑HBV is “making strong progress” in its clinical development, implying that pre‑clinical work, IND‑enabling studies, and possibly the IND filing itself are either completed or near completion.
• Next steps (as inferred from typical development pathways): The next tangible clinical milestones are likely to be the filing (or filing completion) of an IND, followed promptly by the initiation of a Phase 1 trial and the dosing of the first patient(s). Subsequent early‑readout safety and pharmacodynamics data will be the next publicly disclosed checkpoints.

Caveat

The press release excerpt you provided does not specify exact dates, trial identifiers, or detailed milestone timing. For the precise schedule (e.g., “first patient expected Q4 2025” or “IND filing anticipated Q3 2025”), you would need to consult the full earnings release, the company’s investor presentation, or any subsequent shareholder call transcripts where management typically expands on these points.